Targeting the pathobiology of ESCC: Potential impact of immunotherapy on clinical practice

touchEXPERT OPINIONS for touchONCOLOGY Listen to leading experts provide an update on the underlying pathobiology of esophageal squamous cell carcinoma, and review current and emerging therapies. The experts Prof. Ken Kato, National Cancer Center Hospital, Tokyo, Japan Dr Jean-Phillipe Metges, University Hospital of Brest, Brest, France  This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME. For further information visit our website: https://touchoncologyime.org/targeting-pathobio-of-ESCC-and-emerging-impact-of-IO